Vertex to Present at Upcoming Investor Conferences

Rhea-AI Summary

Vertex Pharmaceuticals will have management participation in two upcoming investor conferences. Charles Wagner and David Altshuler will participate in a fireside chat at UBS Biopharma Conference on November 9, 2023. Stuart Arbuckle will participate in a fireside chat at Jefferies London Healthcare Conference on November 14, 2023.

Positive

• Vertex Pharmaceuticals will have management participation in two upcoming investor conferences, which could positively impact the stock price. The conferences provide an opportunity for the company to showcase its research and development efforts and attract investor interest. The presence of high-level executives like Charles Wagner, David Altshuler, and Stuart Arbuckle demonstrates the company's commitment to investor relations and transparency. Investors may view this as a positive sign of the company's growth potential and may be encouraged to buy or hold onto their shares.

Negative

• None.

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.

• Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in a fireside chat at UBS Biopharma Conference on Thursday, November 9, 2023 at 12:00 p.m. ET.
• Stuart Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 8:30 a.m. GMT.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, mRNA, cell and genetic therapies (including gene editing) in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes and alpha-1 antitrypsin deficiency.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20231026949557/en/

Vertex Pharmaceuticals Incorporated Investor Relations:

Susie Lisa, CFA, 617-341-6108

Manisha Pai, 617-961-1899

Miroslava Minkova, 617-341-6135

Source: Vertex Pharmaceuticals Incorporated

FAQ

When and where will the investor conferences take place?

The investor conferences will take place on November 9, 2023 (UBS Biopharma Conference) and November 14, 2023 (Jefferies London Healthcare Conference).

Who will be participating from Vertex Pharmaceuticals?

Charles Wagner, David Altshuler, and Stuart Arbuckle will be participating from Vertex Pharmaceuticals.

Will there be a webcast of the conferences?

Yes, a live webcast of management's remarks will be available through the Vertex website, and a replay of the conference webcast will be archived on the company's website.